C12N 2740/11041
Use of virus, viral particle or viral elements as a vector
C12N2740/11041 (Use of virus, viral particle or viral elements as a vector) appears on 42 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 42
- Published applications
- 42
- Assignees
- 41
- Inventors
- 76
- Latest grant
- 30 Jul 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 1 |
| 2003 | 1 | 0 |
| 2004 | 1 | 3 |
| 2005 | 2 | 1 |
| 2006 | 2 | 6 |
| 2007 | 0 | 0 |
| 2008 | 2 | 2 |
| 2009 | 1 | 2 |
| 2010 | 1 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 2 |
| 2013 | 4 | 2 |
| 2014 | 3 | 4 |
| 2015 | 0 | 1 |
| 2016 | 1 | 3 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 2 | 1 |
| 2020 | 2 | 3 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 2 | 2 |
| 2024 | 2 | 2 |
| 2025 | 0 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2740/11043Viral genome or elements thereof as genetic vectorIndexing code30
- C12N 2740/11045Special targeting system for viral vectorsIndexing code7
- C12N 2740/11044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code6
- C12N 2740/11042Virus or viral particle as vehicleIndexing code4
Recent patents
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon30 Jul 2024US 12,049,639 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon8 Aug 2023US 11,718,861 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Lysosomal storage disease enzymes24 Jan 2023US 11,560,554 B2Alexion Pharmaceuticals, Inc.
- RNA-based delivery systems with levels of control27 Sep 2022US 11,453,893 B2California Institute of Technology
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Glycoproteins for pseudotyping retroviral vector particles25 Dec 2025US 2025/0388924 A1Medizinische Hochschule Hannover
- Alpharetrovirus-based particles for delivery of rna into cells30 Oct 2025US 2025/0333759 A1Medizinische Hochschule Hannover
- Compositions and methods for modifying eukaryotic cells18 Sep 2025US 2025/0290097 A1Orchard Therapeutics (Europe) Limited
- Self-Amplifying RNA-Based VLP Vaccines22 Aug 2024US 2024/0277836 A1Chimeron Bio Corporation
Most cited
By later US patents
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Method of gene transfer into chickens and other avian species102US 5,162,215 AAmgen Inc. · 1992
- Method and means for producing high titer, safe, recombinant lentivirus vectors89US 6,165,782 ACell Genesys, Inc. · 2000
- Retroviral packaging cell lines77US 5,591,624 AChiron Viagene, Inc. · 1997
- Method and means for producing high titer, safe, recombinant lentivirus vectors64US 6,428,953 B1Cell Genesys, Inc. · 2002